Review
Autacoids as modulators of the inflammatory and immune response

https://doi.org/10.1016/0002-9343(81)90264-3Get rights and content

Abstract

Once considered only mediators of inflammation, autacoids, (histamine, prostaglandins and beta-mimetic catecholamines) have been found to be generated during specific early and late phases of immunity. They need sufficient concentrations to affect immunocytes and can modulate immunity usually by inhibiting it. Receptors for the autacoids on the immunocytes are nonrandomly distributed. A small portion of T suppressor cells always appear to have receptors on them, but precursor B cells and precursors of T cells that produce lymphokines or are responsible for cytolysis do not. Instead, as these cells mature they develop their autacoid receptors. With one exception, the function of the immunocytes is inhibited by the effects of autacoids. Again, in all but one instance, that inhibitory modulating effect is mediated by and directly proportional to the intracellular concentrations of cyclic adenosine monophosphate (AMP) generated by the autacoid. The clinical implications of these observations are beginning to be appreciated. One of them is that pharmacologic antagonists of the autacoids can have predictable but hitherto unanticipated effects on immune functions. It is inconceivable that these effects will not have clinical value.

References (48)

  • J.A. Kram et al.

    Cutaneous immediate hypersensitivity in man: effects of systemically administered adrenergic drugs

    J Allergy Clin Immunol

    (1975)
  • A Schwartz et al.

    Histamine inhibition of the in vitro induction of cytotoxic T-cell responses

    Immunopharmacology

    (1980)
  • J Avella et al.

    Effect of histamine H2-receptor antagonists on delayed hypersensitivity

    Lancet

    (1978)
  • H.R. Bourne et al.

    Modulation of inflammation and immunity by cyclic AMP

    Science

    (1974)
  • L.M. Lichtenstein

    The interdependence of allergic and inflammatory processes

  • H.R. Bourne et al.

    Pharmacologic regulation of antibody release in vitro: effects of vasoactive amines and cyclic AMP

  • K.L. Melmon et al.

    Hemolytic plaque formation by leukocytes in vitro: control by vasoactive hormones

    J Clin Invest

    (1974)
  • K.L. Melmon et al.

    Separation of specific antibody-forming mouse cells by their adherence to insolubilized endogenous hormones

    J Clin Invest

    (1974)
  • E.R. Unanue et al.

    Regulation of immunity and inflammation by mediators from macrophages

    Am J Pathol

    (1976)
  • Y Weinstein et al.

    The role of prostaglandin E and cyclic AMP in modulating aspects of the immune response

  • K.L. Melmon et al.

    Inflammatory and immune responses: cell individuality amidst ubiquitous hormonal signals

    Johns Hopkins Med J

    (1977)
  • J.E. Smolen et al.

    Increased levels of cyclic adenosine-3′,5′-monophosphate in human polymorphonuclear leukocytes after surface stimulation

    J Clin Invest

    (1980)
  • S Cohen et al.

    Current state of studies of mediators of cellular immunity: a progress report

    Cell Immunol

    (1977)
  • G.L. Asherson et al.

    Movement to sites of inflammation and non-specific cytotoxicity of T lymphocytes stimulated by antigen in vivo and their resemblance to lymphocytes stimulated with phytohaemagglutinin in vitro

  • Cited by (65)

    • Pro-resolving lipid mediators: Agents of anti-ageing?

      2018, Seminars in Immunology
      Citation Excerpt :

      These tissue manifestations of inflammation are directed by autacoids creating chemical gradients that dictate trafficking of leucocytes to injured tissue. These chemical mediators include peptides, proteins and lipid-derived mediators [2,3]. Initial observations that some lipid-derived mediators acted to inhibit polymorphonuclear cell (PMN) trafficking led to the proposal that they acted as “stop” signals, or brakes, in inflammation.

    • Stinging nettles leaf (Urtica dioica L.): Extraordinary vegetable medicine

      2013, Journal of Herbal Medicine
      Citation Excerpt :

      Besides being a mediator of immediate hypersensitivity allergic reactions, histamine acts as an autacoid (“self medication”) to modulate the immune response. It activates adenylate cyclase via H2-receptors of leukocytes, thereby stimulating the conversion of ATP to cAMP and preventing antigen-induced mediator release from sensitized basophils and mast cells, such as histamine release from ragweed-sensitized cells (Bourne et al., 1974; Melmon et al., 1981). The ability of stinging nettle preparations to inhibit platelet aggregation has been reported in various in vitro models.

    • Periodic fevers with aphthous stomatitis, pharyngitis, and adenitis (PFAPA)

      2012, Autoimmunity Reviews
      Citation Excerpt :

      Cimetidine, a histamine type 2 receptor blocker, was also used, in the past, for the treatment of PFAPA. Cimetidine was shown to have immunomodulating properties such as suppression of CD8 + T-cells, increase INF-gamma production and chemotaxis of neutrophils, increase lysosomal enzyme release and production of migratory inhibitory factors [28,29]. One third of a cohort of children treated with a prophylactic dose of cimetidine of 150 mg twice daily for 6–12 months responded to treatment [7].

    • Use of the A <inf>2A</inf> adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo

      2003, Biochemical Pharmacology
      Citation Excerpt :

      However, this notion has not been widely accepted by investigators outside this field since adenosine receptors are not the only candidates for this role. Activation of some other Gs protein-coupled cAMP-elevating receptors (including histamine, dopamine, prostaglandin, and β2 adrenergic receptors) can also inhibit inflammatory processes in vivo, which led to their consideration as potential physiological OFF signals [79,81,100,101]. Activation of both A2A and A2B receptors is capable of increasing cAMP levels in immune cells, and both receptors had to be considered as potentially immunosuppressive in vivo.

    • Ocular mast cells and mediators

      1997, Immunology and Allergy Clinics of North America
    View all citing articles on Scopus

    This work was supported in part by HL 26340-01.

    1

    From the Department of Medicine, Stanford University School of Medicine, Stanford, California.

    2

    From the Department of Medicine, Tufts University School of Medicine, Boston, Mass.

    View full text